特一藥業(002728.SZ)擬設立特一藥物研究(廣東)有限公司
格隆匯12月25日丨特一藥業(002728.SZ)公佈,公司因公司發展戰略的需要,擬出資1000萬設立全資子公司特一藥物研究(廣東)有限公司(暫定),同時董事會授權公司管理層代表公司依法辦理設立期間的相關事項;其經營範圍:開展中西藥品、中藥材、中藥飲片、食品、保健品、衞生材料、醫療器械、功能化粧品及個人護理品及其原料、配料、中間體等相關的研究開發、技術諮詢、技術轉讓和技術服務以及人員培訓等工作。
此次設立全資子公司是基於業務管理和發展的需要,此次擬以自有資金投資設立全資子公司,不會對公司財務及經營狀況產生不利影響,不存在損害公司及全體股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.